Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
2024; Elsevier BV; Volume: 11; Issue: 2 Linguagem: Inglês
10.1016/s2352-3026(23)00366-6
ISSN2451-9960
AutoresK. Elias, Hartmut Goldschmidt, Kaya Miah, Uta Bertsch, Britta Besemer, Mathias Hänel, Julia Krzykalla, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor Wolfgang Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Christina Kunz, Christoph Mann, Niels Weinhold, Christof Scheid, Roland Schroers, Ivana von Metzler, Aneta Schieferdecker, Jörg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe M. Martens, Christian Künz, Manfred Hensel, Axel Benner, Andrea Seidel-Glätzer, Katja Weisel, Marc S. Raab, Hans Salwender, Nicole Adrian, Helga Bernhard, Hans-Peter Böck, Claus Bolling, Gerrit Dingeldein, Till‐Oliver Emde, Barbara Ferstl, Thomas Fietz, Stefan Fronhoffs, Stephan Fuhrmann, Stefan Fuxius, Thomas Geer, Martin Görner, B. GUENTHER, Frank Hartmann, Bernhard Heilmeier, Michael Heinsch, Martin Hoffmann, Tobias A.W. Holderried, Stefan Klein, Martin Klump, Wolfgang Knauf, Paul La Rosée, Elisabeth Lange, Walter Lindemann, Roderico Lopez, Frank Mayer, Holger Nückel, Eva Papesch, Maria Procaccianti, Alexander Reichart, Mathias Rummel, Lars Scheuer, H. Schmitt, Peter Staib, Heike Steiniger, Hans‐Joachim Tischler, Thomas Ulshöfer, Walter Verbeek, Alexander Wacker, I. Zirpel,
Tópico(s)Protein Degradation and Inhibitors
ResumoThe aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma.
Referência(s)